Merck Kgaa · XETR:MRK
Merck Kgaa — Q1 2025 Earnings Presentation
13 slides from Merck Kgaa's earnings presentation, May 15, 2025
Slide 1: Q1 2025 Results: Merck Continues to Deliver Growth in Turbulent Times
Q1 2025 Results MeRck Continues to Deliver Growth in Turbulent Times
Slide 2: Q1 2025: Merck continues to deliver growth in all three business sectors
1 Q1 2025: Merck continues to deliver growth in all three business sectors. 2 Double-digit growth in Process Solutions, strong CM&E sales and continued semiconductor materials demand. 3 Confident & well-positioned to achieve sustainable growth in 2025.
Slide 3: Disclaimer
Disclaimer Cautionary Note Regarding Forward-Looking Statements and financial indicators This communication may include “forward-looking statements.” Statements that include words such as “anticipate,” “expect,” “should,” “would,” “intend,” “plan,” “project,” “seek,” “believe,” “will,” and other wor
Slide 4: Highlights: Merck Continues to Deliver Growth in Turbulent Times
Highlights: Merck Continues to Deliver Growth in Turbulent Times Operations Group Financials Q1 YoY organic sales growth1 Life Science: Sales growing +3% driven by strong PS growth of +11% Very strong YoY improvement in PS orders Q1 organic sales: +2.5% SLS down -2% with headwinds from US poli
Slide 5: Financial Overview
cy * 7 “ties = a - e, > +. €EMANTIAL. . “? * : ae overview »
Slide 6: Q1 2025: Overview
Q1 2025: Overview Key figures Comments [€m] Q1 2024 Q1 2025 Δ Sales up +3%, driven by org. growth with modest support from FX / portfolio effects Net sales 5,120 5,280 3.1% All sectors contributing org. sales growth EBITDA pre 1,454 1,535 5.6% Margin (in % of net sales) 28.4% 29.1% 0.7pp EBITD
Slide 7: Life Science Q1: Low-teens Process Solutions Growth, Validating Ongoing Recovery
Life Science Q1: Low-teens Process Solutions Growth, Validating Ongoing Recovery Life Science P&L Net sales bridge [€m] IFRS Pre €2,144 m 2.5% 0.6% 0.3% €2,218 m Q1 2024 Q1 2025 Q1 2024 Q1 2025 Net sales 2,144 2,218 2,144 2,218 M&S -551 -555 -545 -554 +0.0% Q1 2024 Organic Currency Portfolio Q1 2025
Slide 8: Healthcare Q1: Continued Profitable Growth Driven by CM&E, Erbitux and Mavenclad
Healthcare Q1: Continued Profitable Growth Driven by CM&E, Erbitux and Mavenclad Healthcare P&L Net sales bridge [€m] IFRS Pre €2,048 m 3.4% 0.0% €2,114 m -0.2% Q1 2024 Q1 2025 Q1 2024 Q1 2025 Net sales 2,048 2,114 2,048 2,114 M&S -398 -411 -395 -411 Q1 2024 Organic Currency Portfolio Q1 2025 Admin
Slide 9: Electronics Q1: Semiconductor Materials is the Key Growth Driver
Electronics Q1: Semiconductor Materials is the Key Growth Driver Electronics P&L Net sales bridge €928 m 0.6% 0.9% 0.6% €948 m [€m] IFRS Pre Q1 2024 Q1 2025 Q1 2024 Q1 2025 Net sales 928 948 928 948 M&S -138 -142 -138 -139 +0.0% Q1 2024 Organic Currency Portfolio Q1 2025 Admin -37 -48 -32 -36 R&D -7
Slide 10: Outlook & Guidance
ie Pr | bes, “3 ipance —.... er Ps e *@ *« . ¢ bad . @ MARR
Slide 11: Merck Group Full-year 2025 guidance
Merck Group Full-year 2025 guidance Net sales: Organic: +2% to +6% YoY FX: -3% to +0% YoY ~€20.9 – €22.4 bn EBITDA pre: Organic: +2% to +7% YoY FX: -5% to -2% YoY ~€5.8 – €6.4 bn EPS pre: ~€7.90 – €9.00 11 Merck Q1 2025 Results Presentation | May 15, 2025
Slide 12: 2025 Business Sector Guidance
2025 Business Sector Guidance1 Net sales EBITDA pre Life Science Organic: +2% to +6% YoY Organic:+1% to +7% YoY FX: -3% to +0% YoY FX: -4% to -1% YoY ~€8.80 bn to €9.40 bn ~€2.50 bn to €2.70 bn Driven by Process Solutions Net sales EBITDA pre Healthcare Organic: +2% to +6% YoY Orga
Slide 13: Q1 2025: Merck continues to deliver growth in all three business sectors
1 Q1 2025: Merck continues to deliver growth in all three business sectors. 2 Double-digit growth in Process Solutions, strong CM&E sales and continued semiconductor materials demand. 3 Confident & well-positioned to achieve sustainable growth in 2025.